Literature DB >> 27668058

Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non-Small-Cell Lung Cancer.

Loretta Fala.   

Abstract

Entities:  

Year:  2016        PMID： 27668058      PMCID： PMC5013862     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  3 in total

1.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Authors:  Nick Thatcher; Fred R Hirsch; Alexander V Luft; Aleksandra Szczesna; Tudor E Ciuleanu; Mircea Dediu; Rodryg Ramlau; Rinat K Galiulin; Beatrix Bálint; György Losonczy; Andrzej Kazarnowicz; Keunchil Park; Christian Schumann; Martin Reck; Henrik Depenbrock; Shivani Nanda; Anamarija Kruljac-Letunic; Raffael Kurek; Luis Paz-Ares; Mark A Socinski
Journal:  Lancet Oncol       Date:  2015-06-01       Impact factor: 41.316

2.  Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.

Authors:  Natasha B Leighl; Natasha Rekhtman; William A Biermann; James Huang; Mari Mino-Kenudson; Suresh S Ramalingam; Howard West; Sara Whitlock; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

3.  Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Authors:  Luis Paz-Ares; Jörg Mezger; Tudor E Ciuleanu; Jürgen R Fischer; Joachim von Pawel; Mariano Provencio; Andrzej Kazarnowicz; György Losonczy; Gilberto de Castro; Aleksandra Szczesna; Lucio Crino; Martin Reck; Rodryg Ramlau; Ernst Ulsperger; Christian Schumann; Jose Elias A Miziara; Álvaro E Lessa; Mircea Dediu; Beatrix Bálint; Henrik Depenbrock; Victoria Soldatenkova; Raffael Kurek; Fred R Hirsch; Nick Thatcher; Mark A Socinski
Journal:  Lancet Oncol       Date:  2015-02-18       Impact factor: 41.316
  3 in total
  4 in total

Review 1.  Complement System: a Neglected Pathway in Immunotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Adrian Tempescul; Christian Berthou; Eléonore Bettacchioli; Sophie Hillion; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 2.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

Review 3.  Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors:  Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

4.  Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes.

Authors:  Katherine Sellers; Thaddeus D Allen; Michael Bousamra; JinLian Tan; Andrés Méndez-Lucas; Wei Lin; Nourdine Bah; Yelena Chernyavskaya; James I MacRae; Richard M Higashi; Andrew N Lane; Teresa W-M Fan; Mariia O Yuneva
Journal:  Br J Cancer       Date:  2019-05-22       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.